- Home
- LENZ vs VIR Comparison
LENZ vs VIR Comparison
Compare LENZ & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LENZ
- VIR
- Stock Information
- Founded
- LENZ 2019
- VIR 2016
- Country
- LENZ United States
- VIR United States
- Employees
- LENZ N/A
- VIR N/A
- Industry
- LENZ Medicinal Chemicals and Botanical Products
- VIR Biotechnology: Pharmaceutical Preparations
- Sector
- LENZ Health Care
- VIR Health Care
- Exchange
- LENZ Nasdaq
- VIR Nasdaq
- Market Cap
- LENZ 795.5M
- VIR 844.9M
- IPO Year
- LENZ 2021
- VIR 2019
- Fundamental
- Price
- LENZ $26.34
- VIR $5.09
- Analyst Decision
- LENZ Strong Buy
- VIR Strong Buy
- Analyst Count
- LENZ 5
- VIR 7
- Target Price
- LENZ $41.80
- VIR $33.57
- AVG Volume (30 Days)
- LENZ 259.1K
- VIR 1.0M
- Earning Date
- LENZ 05-07-2025
- VIR 05-07-2025
- Dividend Yield
- LENZ N/A
- VIR N/A
- EPS Growth
- LENZ N/A
- VIR N/A
- EPS
- LENZ N/A
- VIR N/A
- Revenue
- LENZ N/A
- VIR $20,861,000.00
- Revenue This Year
- LENZ N/A
- VIR N/A
- Revenue Next Year
- LENZ $544.90
- VIR $10.65
- P/E Ratio
- LENZ N/A
- VIR N/A
- Revenue Growth
- LENZ N/A
- VIR N/A
- 52 Week Low
- LENZ $14.42
- VIR $4.95
- 52 Week High
- LENZ $38.93
- VIR $14.45
- Technical
- Relative Strength Index (RSI)
- LENZ 52.07
- VIR 31.53
- Support Level
- LENZ $22.52
- VIR $5.04
- Resistance Level
- LENZ $27.37
- VIR $6.29
- Average True Range (ATR)
- LENZ 2.19
- VIR 0.30
- MACD
- LENZ -0.14
- VIR -0.02
- Stochastic Oscillator
- LENZ 47.99
- VIR 3.57
About LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.